Tumor Biology

, Volume 35, Issue 10, pp 9639–9647 | Cite as

Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip

  • Ming-Yii Huang
  • Hsueh-Chiao Liu
  • Li-Chen Yen
  • Jia-Yuan Chang
  • Jian-Jhang Huang
  • Jaw-Yuan Wang
  • Shiu-Ru Lin
Research Article


The KRAS oncogene was among the first genetic alterations in colorectal cancer (CRC) to be discovered. Moreover, KRAS somatic mutations might be used for predicting the efficiency of anti-epidermal growth factor receptor therapeutic drugs. Because the KRAS mutations are similar in the primary CRC and/or the CRC metastasis, KRAS mutation testing can be performed on both specimen types. The purpose of this study was to investigate the clinical advantage of using a KRAS pathway-associated molecule analysis chip to analyze CRC patients treated with cetuximab. Our laboratory developed a KRAS pathway-associated molecule analysis chip and a weighted enzymatic chip array (WEnCA) technique, activating KRAS detection chip, which can detect KRAS mutation status by screening circulating cancer cells in the bloodstream. We prospectively enrolled 210 stage II–III CRC patients who received adjuvant oxaliplatin plus infusional 5-fluorouracil/leucovorin (FOLFOX)-4 chemotherapy with or without cetuximab. We compared the chip results of preoperative blood specimens with disease control status in these patients. Among the 168 CRC patients with negative chip results, 119 were treated with FOLFOX-4 plus cetuximab chemotherapy, and their relapse rate was 35.3 % (42/119). In contrast, the relapse rate was 71.4 % among the patients with negative chip results who received FOLFOX-4 treatment alone (35/49). Negative chip results were significantly correlated with better treatment outcomes in the FOLFOX-4 plus cetuximab group (P < 0.001). We suggest that the activating KRAS detection chip is a potential tool for predicting clinical outcomes in CRC patients following FOLFOX-4 treatment with or without cetuximab therapy.


Colon cancer Activating KRAS detection chip Cetuximab Recurrence 



Colorectal cancer


Weighted enzymatic chip array






Oxaliplatin plus infusional 5-fluorouracil/leucovorin


Epidermal growth factor receptor


Polymerase chain reaction


Fluorescence in situ hybridization


Circulating tumor cells


Union for International Cancer Control




National Comprehensive Cancer Network



This work was supported by grants from the Excellence for Cancer Research Center Grant through funding by the Ministry of Health and Welfare, Taiwan, Republic of China (MOHW103-TD-B-111-05), the Kaohsiung Medical University Hospital (KMUH101-1M66, KMUH102-2M46), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. All authors read and approved the final manuscript. We would like to acknowledge the helpful comments on this paper received from our reviewers.

Conflicts of interest



  1. 1.
    Frederiksen BL, Jorgensen T, Brasso K, Holten I, Osler M. Socioeconomic position and participation in colorectal cancer screening. Br J Cancer. 2010;103(10):1496–501.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMedGoogle Scholar
  3. 3.
    Department of Health, the Executive Yuan: cancer registry annual report, Taiwan, Republic of China. 2012.Google Scholar
  4. 4.
    Steele Jr G. Standard postoperative monitoring of patients after primary resection of colon and rectum cancer. Cancer. 1993;71(12 Suppl):4225–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995;38(6):619–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol. 2008;9(4–6):357–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, et al. Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cell Signal. 2012;24(1):162–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg. 2010;251(2):254–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24(30):4914–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25(33):5225–32.CrossRefPubMedGoogle Scholar
  14. 14.
    Arnold D, Hohler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol. 2008;19(8):1442–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer. 1998;77(7):1060–5.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Lin SR, Hsu CH, Tsai JH, Wang JY, Hsieh TJ, Wu CH. Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours. Br J Cancer. 2000;82(5):1035–40.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Wu CH, Lee SC, Chiu HH, Yang YC, Lian ST, Shin SJ, et al. Morphologic change and elevation of cortisol secretion in cultured human normal adrenocortical cells caused by mutant p21K-ras protein. DNA Cell Biol. 2002;21(1):21–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Wu CH, Chen YF, Wang JY, Hsieh MC, Yeh CS, Lian ST, et al. Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway. Br J Cancer. 2002;87(9):1000–5.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Chen YF, Chiu HH, Wu CH, Wang JY, Chen FM, Tzou WH, et al. Retinoblastoma protein (pRB) was significantly phosphorylated through a Ras-to-MAPK pathway in mutant K-ras stably transfected human adrenocortical cells. DNA Cell Biol. 2003;22(10):657–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett. 2005;229(1):115–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Chong IW, Chang MY, Sheu CC, Wang CY, Hwang JJ, Huang MS, et al. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. Oncol Rep. 2007;18(1):17–24.PubMedGoogle Scholar
  22. 22.
    Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2009;15(13):4508–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, et al. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens. Genet Mol Res. 2011;10(4):3002–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Yang MJ, Chiu HH, Wang HM, Yen LC, Tsao DA, Hsiao CP, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol. 2010;17(2):624–33.CrossRefPubMedGoogle Scholar
  25. 25.
    De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochem Rev. 2011;32(4):177–95.Google Scholar
  27. 27.
    Ganepola GA, Nizin J, Rutledge JR, Chang DH. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World J Gastrointest Oncol. 2014;6(4):83–97.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Tsao DA, Yang MJ, Chang HJ, Yen LC, Chiu HH, Hsueh EJ, et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients. Lung Cancer. 2010;68(1):51–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ming-Yii Huang
    • 1
    • 2
  • Hsueh-Chiao Liu
    • 3
    • 4
  • Li-Chen Yen
    • 3
  • Jia-Yuan Chang
    • 3
  • Jian-Jhang Huang
    • 3
  • Jaw-Yuan Wang
    • 6
    • 7
  • Shiu-Ru Lin
    • 5
  1. 1.Department of Radiation Oncology, Cancer CenterKaohsiung Medical University HospitalKaohsiungTaiwan
  2. 2.Department of Radiation Oncology, Faculty of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  3. 3.Personalized Medical Service Center, Division of Laboratory MedicineFooyin University HospitalPingtungTaiwan
  4. 4.Institute of Biomedical SciencesNational Sun Yat-San UniversityKaohsiungTaiwan
  5. 5.Division of Medical ResearchFooyin University HospitalPingtungTaiwan
  6. 6.Division of Gastrointestinal and General Surgery, Department of Surgery CancerKaohsiung Medical University HospitalKaohsiungTaiwan
  7. 7.Department of Surgery, Graduate Institute of Clinical Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan

Personalised recommendations